';
+44 141 248 2026info@evolution-bio.comNewsletter Sign-UpDownload Our BrochureEvolution Executive Search
logo
Evolution Bioscience
logo
  • Home
  • Clients & Core Services
  • News & Analysis
    • The Future of BioManufacturing
  • IPO Tracker

Author Archives: evolutionbio

Evolution Infographics
Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment
Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment
More
Share
Evolution Infographics
2018 Global Drug Development IPO Review: $10.24B Raised in Strongest Year on Record
2018 Global Drug Development IPO Review: $10.24B Raised in Strongest Year on Record
More
Share
Evolution Infographics
RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval
RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval
More
Share
Evolution Infographics
Global Drug Development IPOs: 26 Companies Raise Over $3.18B in Q3 as First Pre-Revenue Biotechs List in Hong Kong
Global Drug Development IPOs: 26 Companies Raise Over $3.18B in Q3 as First Pre-Revenue Biotechs List in Hong Kong
More
Share
News & Analysis
Democratising DNA: 23andMe & GSK Collaboration Highlights Data Quality & Privacy Concerns; Can Blockchain Offer a Disruptive Solution?
Democratising DNA: 23andMe & GSK Collaboration Highlights Data Quality & Privacy Concerns; Can Blockchain Offer a Disruptive Solution?
More
Share
Evolution Infographics
Global Drug Development IPOs: Over $2.5B Raised in Q2 with Market on Track for Best Year Since 2015
Global Drug Development IPOs: Over $2.5B Raised in Q2 with Market on Track for Best Year Since 2015
More
Share
Evolution Infographics
Lonza Opens the World’s Largest Cell & Gene Therapy Manufacturing Plant in Texas
Lonza Opens the World’s Largest Cell & Gene Therapy Manufacturing Plant in Texas
More
Share
Evolution Infographics
All Eyes on Oxford Nanopore after further £100m funding raised at £1.5B Valuation
All Eyes on Oxford Nanopore after further £100m funding raised at £1.5B Valuation
More
Share
Evolution Infographics
Charles River Laboratories M&A Activity Analysis: A Differentiated Strategy Delivering Results
Charles River Laboratories M&A Activity Analysis: A Differentiated Strategy Delivering Results
More
Share
News & Analysis
More Efficient and Affordable Large-Scale Biomanufacturing: Have Novo Nordisk Foundation Made a Major Breakthrough?
More Efficient and Affordable Large-Scale Biomanufacturing: Have Novo Nordisk Foundation Made a Major Breakthrough?
More
Share
Evolution Infographics
Global Drug Development IPO Review: $6.4B Raised as Bullish Investors Back Biologics & Gene Therapies Despite Slowed Growth in 2017
Global Drug Development IPO Review: $6.4B Raised as Bullish Investors Back Biologics & Gene Therapies Despite Slowed Growth in 2017
More
Share
Evolution Infographics
Manufacturing Gene Therapies: An Impending Crisis or Temporary Growing Pains?
Manufacturing Gene Therapies: An Impending Crisis or Temporary Growing Pains?
More
Share
Evolution Infographics
Evaluating the Monogenic Gene Therapy Pipeline: Will Spark Therapeutics’ Luxturna Avoid the Fate of Glybera & Strimvelis?
Evaluating the Monogenic Gene Therapy Pipeline: Will Spark Therapeutics’ Luxturna Avoid the Fate of Glybera & Strimvelis?
More
Share
Evolution Infographics
Evotec Invests €15m in Exscientia in Latest Partnership between Big Pharma & Artificial Intelligence-Driven Drug Discovery
Evotec Invests €15m in Exscientia in Latest Partnership between Big Pharma & Artificial Intelligence-Driven Drug Discovery
More
Share
Evolution Infographics
2017 Global Therapeutic IPO Market: 121% YOY Increase in Funds Raised Despite Bearish Q3
2017 Global Therapeutic IPO Market: 121% YOY Increase in Funds Raised Despite Bearish Q3
More
Share
Next
  • 1
  • 2
  • 3

Categories

  • Evolution Infographics
  • News & Analysis

About Us

Evolution Bioscience is a global consultancy firm, specialising in market intelligence, strategy formulation, technology transfer and commercialisation services, covering the full range of Biotechnology sectors.

Recent Posts

Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment
Cell & Gene Therapy: Increasing Demand for Viral Vectors Drives Biomanufacturing Innovation & CDMO Investment
2018 Global Drug Development IPO Review: $10.24B Raised in Strongest Year on Record
2018 Global Drug Development IPO Review: $10.24B Raised in Strongest Year on Record
RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval
RNAi Therapeutics Come of Age: Exploring the Peaks & Troughs of Alnylam’s Thirty Year Journey to First Approval
Global Drug Development IPOs: 26 Companies Raise Over $3.18B in Q3 as First Pre-Revenue Biotechs List in Hong Kong
Global Drug Development IPOs: 26 Companies Raise Over $3.18B in Q3 as First Pre-Revenue Biotechs List in Hong Kong
2016 © Evolution Bioscience / Darwin Hutton Partners
Evolution Bioscience